Thursday, May 17, 2012
Two academic teams have independently shown that targeting
the inflammasome reduces retinal damage in mouse models of age-related macular
degeneration.1,2 One study favors inhibiting inflammasome activation
to treat dry AMD, whereas the other suggests boosting it to treat wet AMD. The
approach for treating dry AMD has been licensed to iVeena Pharmaceuticals Inc., and the
academics focused on wet AMD are developing their own gene therapy.
To serve and
The dry path
Wet and dry
Fulmer, T. SciBX 5(20);
doi:10.1038/scibx.2012.511 Published online May 17, 2012
1. Doyle, S.L. et al. Nat. Med.; published online April 8, 2012; doi:10.1038/nm.2717 Contact: Matthew Campbell, Trinity College Dublin, Dublin, Ireland
2. Tarallo, V. et al. Cell; published online April 26, 2012;
Jayakrishna Ambati, University of Kentucky, Lexington, Ky. e-mail: email@example.com
3. Henao-Mejia, J. et al. Nat. Immunol. 13, 321-324 (2012)
4. Zitvogel, L. et al. Nat. Immunol. 13, 343-351 (2012)
5. Duewell, P. et al. Nature 464, 1357-1361
6. Masters, S.L. et al. Nat. Immunol. 11, 897-904 (2010)
7. Martinon, F. et al. Nature 440, 237-241 (2006)
8. Iyer, S.S. et al. Proc. Natl.
Acad. Sci. USA 106, 20388-20393 (2009)
9. Kaneko, H. et al. Nature 471, 325-330 (2011)
Acucela Inc., Seattle, Wash.
Cleveland Clinic Lerner College of Medicine of Case Western
Reserve University, Cleveland,
Harvard Medical School, Boston, Mass.
iVeena Pharmaceuticals Inc., Salt Lake City, Utah
Trinity Biomedical Sciences Institute, Dublin, Ireland
Trinity College Dublin, Dublin, Ireland
University of Kentucky, Lexington, Ky.